ePT--the Electronic Newsletter of Pharmaceutical Technology
South San Francisco, CA (Mar. 28)-Genentech, Inc. announced plans to invest $140 million in 1000-liter manufacturing facility in Singapore.
South San Francisco, CA (Mar. 28)-Genentech, Inc. (www.gene.com) announced plans to invest $140 million in a 1000L manufacturing facility in Singapore.
Construction on the new facility is slated to begin in the second quarter of 2007, and the company expects it to be fully licensed by 2010. The new site will manufacture “Lucentis,” Genentech’s treatment for neovascular (wet) age-related macular degeneration, which received approval from the US Food and Drug Administration in June 2006.
Singapore recently has proven popular with other drug giants. GlaxoSmithKline (London, www.gsk.com) is building a $190-million vaccine plant there. In August 2006, Lonza (Basel, Switzerland, www.lonza.com) announced plans to build a $250-million large-scale mammalian cell-culture plant in Singapore.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.